Coya Therapeutics Q2 2023 net loss $3.1M; highlights positive AD and ALS clinical data

Coya Therapeutics, Inc.

2023-Q2 EPS reported -$0.59

Net loss of $3.1M ($0.31 per share) for Q2 2023 vs $3.4M loss in Q2 2022.
Cash and equivalents $13.1M as of June 30, 2023, up from $5.9M at Dec 31, 2022.
Positive PoC data for ld IL-2 in Alzheimer's: statistically significant MMSE improvement and reduced neuroinflammation.
ALS study of COYA 302 halted disease progression at 24 weeks; pre-IND meeting with FDA planned for H2 2023.
Appointed Dr. Fred Grossman as President/CMO and Arun Swaminathan as CBO.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

Coya Therapeutics, Inc. reported financial results for second quarter ended June 30, 2023.

Period: second quarter ended June 30, 2023
Result: reported results

Exact text from the filing

On August 8, 2023, Coya Therapeutics, Inc. (the “Company”) issued a press release disclosing certain information regarding its results of operations for the fiscal quarter ended June 30, 2023.

View on SEC.gov

171 earnings releases filed in the last 30 days. Browse all earnings releases →

Coya Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-039348

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.